Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.65 |
| ▸ | CDK1 | P06493 | 2/20 | 0.56 |
| ▸ | CDK2 | P24941 | 2/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.54 |
| ▸ | SMPD3 | Q9NY59 | 3/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31227772 | 1.00 | HRH3 (0.65) | HRH3CDK1CDK2HRH4SMPD3 | |
| SCHEMBL31227534 | 1.00 | HRH3 (0.65) | HRH3CDK1CDK2HRH4SMPD3 | |
| SCHEMBL31227587 | 0.91 | HRH3 (0.57) | HRH3CDK1CDK2HRH4SMPD3 | |
| SCHEMBL31227779 | 0.91 | HRH3 (0.57) | HRH3CDK1CDK2HRH4SMPD3 | |
| SCHEMBL31246523 | 0.91 | HRH3 (0.57) | HRH3CDK1CDK2HRH4SMPD3 | |
| SCHEMBL27730153 | 0.87 | HRH3 (0.58) | HRH3CDK1CDK2HRH4ROCK1 | |
| SCHEMBL31227206 | 0.87 | HRH3 (0.58) | HRH3CDK1CDK2HRH4ROCK1 | |
| SCHEMBL13018656 | 0.83 | HRH3 (0.82) | HRH3HRH4 | |
| SCHEMBL18691295 | 0.83 | HRH3 (0.71) | HRH3CDK1CDK2HRH4CCNC | |
| SCHEMBL17626721 | 0.83 | HRH3 (0.71) | HRH3CDK1CDK2HRH4CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | HRH3 3980/4885CDK1 501/4885CDK2 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.